July 23, 2026

GLP-1 receptor agonist peptides have become one of the most active areas of metabolic and endocrinology research. These compounds mimic glucagon-like peptide-1, a hormone that acts on GLP-1 receptors expressed in the pancreas, gut, and central nervous system. For laboratory scientists, the interest is straightforward: this class offers a well-defined mechanism, a growing body of published data, and a range of structural variations worth studying.
This post covers the current research picture, the peptides most often referenced in the literature, and the practical quality-control points that matter when sourcing these materials. Everything here is written for research use only. These peptides are not for human consumption, and nothing below should be read as dosing, administration, or medical guidance.
GLP-1 receptor agonists are peptides that bind and activate the GLP-1 receptor, a class B G-protein-coupled receptor. Native GLP-1 is degraded quickly by the enzyme DPP-4, which limits its half-life. The peptides studied today are engineered to resist that degradation, most commonly through amino acid substitutions and fatty-acid acylation that promotes albumin binding.
Research on this class generally falls into a few buckets:
The field has expanded beyond single-receptor agonists into multi-receptor designs, which is where much of the newer literature sits.
The distinction between agonist types is the clearest way to organize this class.
Single agonists target the GLP-1 receptor alone. Semaglutide is the most widely referenced example, studied extensively in metabolic research and used as a comparator in many receptor-pharmacology experiments. Researchers working with it often reference as a benchmark GLP-1 agonist.
Dual agonists act on two receptors at once. Tirzepatide engages both the GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. The dual-incretin approach has generated substantial interest in comparative signaling and metabolic studies, and tirzepatide frequently appears in structure-activity investigations alongside single agonists.
Triple agonists add a third target. Retatrutide is designed to activate GLP-1, GIP, and glucagon receptors. As one of the newer compounds in this class, retatrutide is a frequent subject in research comparing multi-receptor pharmacology.
GLP-1 agonists are long, acylated peptides, which makes them harder to synthesize cleanly than short unmodified sequences. Impurities in this class tend to come from incomplete acylation, deletion sequences, and aggregation. That makes analytical verification essential before any experiment.
When evaluating research-grade GLP-1 agonists, the specifications that carry weight are:
A reputable Canadian supplier such as Peptide Depot should provide a batch-specific certificate of analysis reflecting these measurements. You can review general sourcing and product information through the product catalog.
GLP-1 agonist peptides are supplied as lyophilized powder and should be treated as temperature-sensitive from the moment they arrive. General handling practice for this class:
Researchers often use a Peptide Calculator to standardize concentrations across experiments, which helps keep reconstitution consistent between batches and researchers.
A certificate of analysis (COA) is the single most useful document a supplier provides. For GLP-1 agonists specifically, here is how to read one critically.
If a supplier can't produce a batch-specific COA with these elements, that's a reason to look elsewhere.
A few recurring problems show up in work with this class:
The GLP-1 agonist class continues to generate new structural variants and new questions. For laboratory researchers in Canada, the practical priorities stay constant: verify purity, confirm identity by mass, control storage, and document everything at the batch level. For more general sourcing questions, see the Peptide Depot FAQ.
Single agonists act only on the GLP-1 receptor. Dual agonists act on two receptors, such as GLP-1 and GIP. Triple agonists add a third target, typically the glucagon receptor. The distinction reflects how many receptor pathways the peptide engages, which is a common focus of comparative pharmacology research.
Look for a stated purity of 98% or higher by HPLC, confirmed by a batch-specific certificate of analysis. Mass spectrometry should verify the peptide matches its expected molecular weight, and Karl Fischer titration should report residual water content.
Lyophilized GLP-1 agonist peptides are generally stored at -20°C for medium-term storage or -80°C for longer periods. Reconstituted solutions are less stable, are kept refrigerated, and freeze-thaw cycles should be minimized to prevent aggregation and degradation.
No. The GLP-1 agonist peptides supplied for laboratory work are for research use only and are not for human consumption. They are intended solely for in vitro and laboratory research applications.
A batch-specific COA confirms the purity, identity, and water content of the exact lot you received. A generic or reused COA does not describe your material, which can introduce error into concentration calculations and confound experimental results.